Why the study?
Rituximab-based immunochemotherapy is the standard first-line treatment for PMBCL, but this standard is not based on results from randomized clinical trials.
Does DA-EPOCH-R-28 improve overall survival compared to R-CHOP-21 in patients with primary mediastinal B-cell lymphoma?
Population
53 PMBCL patients
Comparison
R-CHOP-21 vs DA-EPOCH-R-28
Design
Retrospective study
Authors
Loading...
R-CHOP-21 and DA-EPOCH-R yield comparable PMBCL outcomes; leaves open optimal first-line choice pending randomized trials.
Does DA-EPOCH-R-28 improve overall survival compared to R-CHOP-21 in patients with primary mediastinal B-cell lymphoma?
Retrospective analysis suggests R-CHOP-21 may be a viable alternative to DA-EPOCH-R for PMBCL, with potentially fewer low-grade cardiologic complications.
Malenda et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: